BRIEF-Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501

Reuters

02-14

BRIEF-Allogene <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501

Feb 13 (Reuters) - Allogene Therapeutics Inc ALLO.O:

ALLOGENE THERAPEUTICS ANNOUNCES PUBLICATION OF DURABLE RESPONSE DATA FROM PHASE 1 ALPHA/ALPHA2 TRIALS OF THE ALLOGENEIC CAR T CEMACABTAGENE ANSEGEDLEUCEL/ALLO-501 IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY
ALLOGENE THERAPEUTICS INC - CEMA-CEL ACHIEVES ORR OF 58% AND CR OF 42% IN STUDY

Source text: ID:nGNX75ZxGV

Further company coverage: ALLO.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2511848505"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2511848505\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2511848505?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-14 06:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511848505","market":"us","top_or_hot":-1,"title":"BRIEF-Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501</title></head><body><p><span>Feb 13 (Reuters)</span><span> - </span>Allogene Therapeutics Inc <span>ALLO.O</span>:</p><ul><li><p>ALLOGENE THERAPEUTICS ANNOUNCES PUBLICATION OF DURABLE RESPONSE DATA FROM PHASE 1 ALPHA/ALPHA2 TRIALS OF THE ALLOGENEIC CAR T CEMACABTAGENE ANSEGEDLEUCEL/ALLO-501 IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY</p></li><li><p>ALLOGENE THERAPEUTICS INC - CEMA-CEL ACHIEVES ORR OF 58% AND CR OF 42% IN STUDY</p></li></ul><p>Source text: <span>ID:nGNX75ZxGV</span></p><p>Further company coverage: <span>ALLO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BRIEF-Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-14 06:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<title>BRIEF-Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501</title><p><span>Feb 13 (Reuters)</span><span> - </span>Allogene Therapeutics Inc <span>ALLO.O</span>:</p><ul><li><p>ALLOGENE THERAPEUTICS ANNOUNCES PUBLICATION OF DURABLE RESPONSE DATA FROM PHASE 1 ALPHA/ALPHA2 TRIALS OF THE ALLOGENEIC CAR T CEMACABTAGENE ANSEGEDLEUCEL/ALLO-501 IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY</p></li><li><p>ALLOGENE THERAPEUTICS INC - CEMA-CEL ACHIEVES ORR OF 58% AND CR OF 42% IN STUDY</p></li></ul><p>Source text: <span>ID:nGNX75ZxGV</span></p><p>Further company coverage: <span>ALLO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA7ZBDSB:1","article_id":"2511848505","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511848505","pubTimestamp":1739484940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501Feb 13 (Reuters) - Allogene Ther","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALLO":"Allogene Therapeutics Inc.","BK4505":"高瓴资本持仓"},"translate_title":"简介-Allogene Therapeutics宣布公布同种异体Car T Cemacabtagene Ansegedleucel/Allo-501的1期Alpha/Alpha2试验的持久应答数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":0.9},"content_text":"BRIEF-Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501Feb 13 (Reuters) - Allogene Therapeutics Inc ALLO.O:ALLOGENE THERAPEUTICS ANNOUNCES PUBLICATION OF DURABLE RESPONSE DATA FROM PHASE 1 ALPHA/ALPHA2 TRIALS OF THE ALLOGENEIC CAR T CEMACABTAGENE ANSEGEDLEUCEL/ALLO-501 IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGYALLOGENE THERAPEUTICS INC - CEMA-CEL ACHIEVES ORR OF 58% AND CR OF 42% IN STUDYSource text: ID:nGNX75ZxGVFurther company coverage: ALLO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0}}}